Recombinant Human Growth Hormone R (GHR) Protein, His-Tag, 50 µg

Background
Growth hormone receptor (GHR) is also known as somatotropin receptor, growth hormone-binding protein (GHBR), which belongs to the type I cytokine receptor family or Type 1 subfamily. GHR contains one fibronectin type-III domain. GHR / GHBR is expressed in various tissues with high expression in liver and skeletal muscle. The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. GHR is receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway. The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.

Source
Recombinant Human Growth Hormone R (GHR) Protein (Human Growth Hormone R, His Tag (GHR-H5222) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Tyr 264 (Accession # P10912-1).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 29.6 kDa. The protein migrates as 40-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Bioactivity
Please refer to product data sheet.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis"
Untch, Pérol, Mayer et al
Eur J Cancer (2024) 202, 113977
(2) "Dawn-to-dusk dry fasting decreases circulating inflammatory cytokines in subjects with increased body mass index"
Al Lami, Kurtca, Atique et al
Metabol Open (2024) 21, 100274
(3) "Human milk-specific fat components enhance the secretion of ghrelin by MGN3-1 cells"
Kaneko, Taniguchi, Funatsu et al
Biosci Biotechnol Biochem (2024)
Showing 1-3 of 8628 papers.